Full history for every metric is available with a Kvantra account
Reunion Neuroscience Inc. (REUN.TO)
Key financial summary
Financials in CAD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | CAD m | - | - | 0 | 1 | 5 | 0 | 0 |
| Operating profit | CAD m | -20 | -29 | |||||
| Net profit | CAD m | - | - | -3 | -23 | -55 | -48 | -48 |
| EPS reported | CAD | -4.17 | -4.17 | |||||
| Operating cashflow per share | CAD | -2.40 | -2.40 | |||||
| Capex per share | CAD | 0.02 | 0.02 | |||||
| FCF per share | CAD | -2.42 | -2.42 | |||||
| Free cash flow | CAD m | -28 | -28 | |||||
| Net debt | CAD m | -24 | -27 | |||||
| Book value equity | CAD m | 21 | 21 | |||||
| Book value per share | CAD | 1.83 | 1.83 | |||||
| Number of shares | m | 11.64 | 11.64 | |||||
| DPS (TTM paid) | CAD | 0.00 | 0.00 |
Financial summary
Financials in CAD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.51 | 0.78 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -0.38 | -0.59 | |||||
| EV/EBITDA LTM | x | 0.76 | 0.41 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -447.94% | -293.37% | |||||
| FCF Yield | % | -260.15% | -169.26% | |||||
| Quality | ||||||||
| ROE | % | -227.72% | -109.89% | |||||
| ROIC | % | -82.61% | -82.61% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -100.00% | -100.00% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -8.36 | -8.36 | |||||
| Net Debt/EBITDA | x | 1.39 | 1.39 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -220.14% | -163.47% | |||||
| Net debt/Equity | x | -1.12 | -1.28 | |||||
| Gross debt/equity | x | 0.16 | 0.16 | |||||
Company overview
Field Trip Health Ltd. is a company based in Toronto, Canada, that specializes in developing and delivering psychedelic-assisted therapies across North America. The firm manages Field Trip Health Centres, which administer psychedelic treatments, and offers Field Trip Digital applications. Additionally, through its Field Trip Discovery division, it conducts research to create innovative psychedelic molecules. The company provides ketamine-assisted therapy for various conditions, including depression, anxiety, and addiction. Field Trip Health Ltd. was founded in 2008.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Reunion Neuroscience Inc. (REUN.TO)
Field Trip Health Ltd. is a company based in Toronto, Canada, that specializes in developing and delivering psychedelic-assisted therapies across North America. The firm manages Field Trip Health Centres, which administer psychedelic treatments, and offers Field Trip Digital applications. Additionally, through its Field Trip Discovery division, it conducts research to create innovative psychedelic molecules. The company provides ketamine-assisted therapy for various conditions, including depression, anxiety, and addiction. Field Trip Health Ltd. was founded in 2008.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free